JBI, Wolters Kluwer expand partnership for OvidSP solution
As part of the contract, JBI will use Wolters Health’s Ovid platform, as a complete channel for EBP solution on its OvidSP and Nursing@Ovid research platforms. Through the
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).